Now Playing
Opinion|Videos|December 19, 2024
CGM: Redefining Type 2 Diabetes Management
Author(s)Davida Kruger, MSN, APN-BC, BC-ADM
A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the primary barriers to achieving early and consistent glycemic control in T2D patients?
- How can CGM technology help clinicians address therapeutic inertia in diabetes care?
- What role does CGM play in reducing the time patients spend with suboptimal glucose management?
- How can managed care organizations support earlier adoption of CGM in newly diagnosed T2D patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
2
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
3
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
4
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
5
